|
5/13/13 |
FDA Accepts Biogen Idec’s Biologics License Application
for First Long-Lasting Factor VIII Therapy for Hemophilia A |
|
|
|
|
|
Patent Protection for TAL Effector Technology Enables
Licensing Path for Life Technologies Customers |
|
|
|
|
|
Agilent
Technologies Introduces AdvanceBio Peptide Mapping Columns |
|
|
|
|
5/10/13 |
Novartis drug Ilaris® approved by FDA to treat active
systemic juvenile idiopathic arthritis, a serious form of childhood
arthritis |
|
|
|
|
|
GSK:
BREO™ ELLIPTA™ gains US approval for the treatment of
COPD |
|
|
|
|
|
Lilly Announces Enzastaurin Phase
III Study Did Not Meet Primary Endpoint in Diffuse Large B-Cell Lymphoma |
|
|
|
|
5/09/13 |
GSK and Save the Children form unique partnership to save
the lives of one million children
An
ambitious new partnership to save the lives of a million of the poorest
children in the world has been launched by GSK and Save the Children |
|
|
|
|
|
GSK enters new commitment with the GAVI Alliance to
supply cervical cancer vaccine for girls in the world’s poorest
countries
GlaxoSmithKline (GSK) today announced a new commitment to the GAVI
Alliance to supply its cervical cancer vaccine as part of a new long
term programme to help protect girls against cervical cancer in the
world’s poorest countries. |
|
|
|
|
|
GARDASIL® [Human Papillomavirus Quadrivalent (Types 6,
11, 16, and 18) Vaccine, Recombinant], Merck’s HPV Vaccine, Available to
Developing Countries through UNICEF Tender |
|
|
|
|
|
Amgen And Zhejiang Beta Pharma Announce Planned Joint
Venture In China |
|
|
|
|
5/08/13 |
Merck Announces FDA Acceptance of Biologics License
Application for Investigational Ragweed Pollen Sublingual Allergy
Immunotherapy Tablet |
|
|
|
|
5/07/13 |
Millenium:
Meta-Analysis of VELCADE® (bortezomib)-Based Induction
Therapy Followed by Stem-Cell Transplantation Showed Significantly
Greater Response and Longer Progression-Free and Overall Survival in
Patients with Multiple Myeloma |
|
|
|
|
|
Amgen Announces Top-Line Results of Vectibix® (panitumumab)
Phase 3 Head-to-Head Study Against Erbitux® (cetuximab) in Metastatic
Colorectal Cancer |
|
|
|
|
|
GSK gives update on plans to share detailed clinical
trial data as part of its commitment to transparency
GlaxoSmithKline (GSK) today announced progress on its commitment to
share more detailed data from its clinical trials. |
|
|
|
|
5/06/13 |
BMS:
Sub-Group Analysis Shows Investigational Metreleptin
Treatment Demonstrated Reductions in HbA1c, Triglycerides and Liver
Function Tests in Pediatric Patients with Lipodystrophy During a
12-Month Period |
|
|
|
|
5/03/13 |
FDA Approves Merck’s LIPTRUZET™ (ezetimibe and
atorvastatin), a New Product That Can Help Powerfully Lower LDL
Cholesterol |
|
|
|
|
|
Bristol-Myers Squibb Receives US FDA sNDA Approval for
Use of SUSTIVA® (efavirenz) in HIV-1 Infected Pediatric Patients |
|
|
|
|
5/02/13 |
Gilead Reports Interim Data From Phase 2 LONESTAR Study
|
|
|
|
|
|
Regulatory update: Trametinib US PDUFA date extended to 3
September 2013 |
|
|
|
|
5/01/13 |
Merck Announces New $15 Billion Share Repurchase Program |
|
|
|
|
|
GSK announces regulatory submission for umeclidinium
monotherapy in US |
|
|
|
|
|
GSK today announced
that the US Prescription Drug User Fee Act (PDUFA) goal date for
trametinib, its MEK inhibitor, has been extended by 3 months to 3
September 2013. |
|
|
|
|
4/30/13 |
GlaxoSmithKline plc
today announced the submission of a regulatory application in the US for
the investigational once-daily medicine, umeclidinium bromide (UMEC),
for patients with chronic obstructive pulmonary disease (COPD). |
|
|
|
|
4/29/13 |
Bruker Expands Capabilities of MALDI Biotyper Platform
for Microbiology |
|
|
|
|
|
Merck Wins FOSAMAX® (alendronate sodium) Federal
Bellwether Trial Involving Atypical Femur Fracture Claims |
|
|
|
|
|
Gilead Receives Complete Response Letters from U.S. Food
and Drug Administration for Elvitegravir and Cobicistat |
|
|
|
|
|
Incyte Achieves $25 Million Milestone as c-MET Inhibitor
INC280 Advances Into Phase II Development |
|
|
|
|
4/26/13 |
Expanded Control of Shimadzu LC Systems for Empower(TM)
Software - Waters Empower(TM) Software Now Controls Shimadzu Nexera X2
Series Products |
|
|
|
|
|
Life Technologies Supports Global Effort to Help
Accelerate Emergency Screening of Avian Influenza (H7N9) Virus |
|
|
|
|
4/25/13 |
Shimadzu's novel Imaging Mass Microscope, iMScope,
enables optical microscopic observing samples to be mass spectrometric
analyzed directly in the one instrument. - Application in disease
biomarker research and biological function studies |
|
|
|
|
|
Roche Turkey visits hospitals to hand presents to
children with cancer |
|
|
|
|
4/23/13 |
Bayer CropScience and KeyGene enter into research agreement to develop
improved crop varieties – initial focus on wheat more |
|
|
|
|
|
Data from Phase 3 Studies of Gilead’s Sofosbuvir for Hepatitis C |
|
|
|
|
|
Novartis once-daily QVA149 shows superior efficacy in reducing
exacerbations, improving lung function and quality of life in COPD
patients |
|
|
|
|
4/22/13 |
Merck Enters Agreement with Bristol-Myers Squibb to Conduct a Phase II
Clinical Trial Evaluating Combination of Investigational Oral Candidates
MK-5172 and Daclatasvir for Chronic Hepatitis C |
|
|
|
|
4/19/13 |
Amgen Announces Top-Line Results Of Phase 3 Talimogene Laherparepvec
Trial In Melanoma |
|
|
|
|
|
Alcon announces FDA approval of Simbrinza(TM) Suspension, a new beta
blocker-free, fixed-combination therapy for glaucoma patients |
|
|
|
|
4/18/13 |
Bruker and the Genome British Columbia Proteomics Centre at the
University of Victoria Announce Collaboration on Development of High
Throughput iMALDI Assays |
|
|
|
|
|
AB SCIEX and LECO Partner to Offer Combined Solutions for GC/MS and
LC/MS to Metabolomics Researchers |
|
|
|
|
|
Eurofins Collaborates with AB SCIEX and Phenomenex to Improve Analysis
of Animal Feed |
|
|
|
|
|
Abbott Announces FDA Approval and U.S. Launch of the TECNIS® Toric
Intraocular Lens for Cataract Patients |
|
|
|
|
4/17/13 |
GSK:
FDA Advisory Committee recommends approval of BREO(TM) ELLIPTA(TM) for
the treatment of COPD |
|
|
|
|
|
Lilly Acquires Novel Tau Tangle Diagnostic Program to Bolster
Alzheimer's Disease Research and Development
|
|
|
|
|
4/16/13 |
Bayer CropScience and Monsanto Enter into Cross-Licensing Agreements for
Next-Generation and Enabling Technologies |
|
|
|
|
|
Lilly Announces Positive Results of Phase III Trials of Dulaglutide in
Type 2 Diabetes |
|
|
|
|
4/16/13 |
Bayer Initiates Phase III Trial of Investigational
Inhaled Amikacin Solution (BAY41-6551T) in Mechanically Ventilated
Patients with Gram-negative Pneumonia |
|
|
|
|
|
Merck Opens New Manufacturing Facility in Hangzhou, China
|
|
|
|
|
|
Lilly Announces Positive Results of Phase III Trials of
Dulaglutide in Type 2 Diabetes |
|
|
|
|
4/15/13 |
Thermo Fisher Scientific to Acquire Life Technologies
Corporation |
|
|
|
|
|
Agilent Technologies Introduces Enhanced NMR
Data-Acquisition Software, Providing Optimal Speed and Spectral Quality
with Minimal Effort |
|
|
|
|
4/11/13 |
Life Technologies Launches New Bioinformatics Software
Platform Enabling Bio-Design and Gene Synthesis from Next Generation
Sequencing Data |
|
|
|
|
|
Roche Group posts strong sales growth in the first
quarter |
|
|
|
|
4/10/13 |
Pfizer Palbociclib (PD-0332991) Receives Food And Drug
Administration Breakthrough Therapy Designation For Potential Treatment
Of Patients With Breast Cancer |
|
|
|
|
|
Abbott's Galectin-3 Test Provides Doctors in Europe with
New Tool for Assessing the Prognosis of Chronic Heart Failure Patient |
|
|
|
|
|
Merck Announces FDA Acceptance of New Drug Application
for an Investigational Tablet Formulation of the Antifungal NOXAFIL® (posaconazole) |
|
|
|
|
4/08/13 |
Gilead Submits New Drug Application to U.S. FDA for
Sofosbuvir for the Treatment of Hepatitis C
|
|
|
|
|
4/07/13 |
Meta-Analysis of VELCADE® (bortezomib)-Based Induction
Therapy Followed by Stem-Cell Transplantation Showed Significantly
Greater Response and Longer Progression-Free and Overall Survival in
Patients with Multiple Myeloma
|
|
|
|
|
4/05/13 |
Takeda and Millennium Announce Approval of ADCETRIS® (Brentuximab
Vedotin) in Switzerland |
|
|
|
|
4/04/13 |
The Lancet Publishes SELECT Study Evaluating Efficacy and
Safety of Daclizumab HYP in Multiple Sclerosis |
|
|
|
|
|
Roche launches new test for diagnosis and monitoring of
thyroid cancer |
|
|
|
|
4/03/13 |
Thermo Fisher Scientific to Hold Earnings Conference Call
on Wednesday, April 24, 2013 |
|
|
|
|
|
GlaxoSmithKline announces start of phase III study of
Benlysta® (belimumab ) in patients with vasculitis |
|
|
|
|
|
GSK announces first four-strain seasonal influenza
vaccine granted marketing authorisation in Germany and the UK
GlaxoSmithKline plc has announced the marketing
authorization of its quadrivalent (four-strain) influenza vaccine in
Germany and the UK. |
|
|
|
|
4/02/13 |
Potential Lilly Investment Would Further Expand
Indianapolis Insulin Manufacturing Operations
|
|
|
|
|
|
Biogen Idec Completes Purchase of Full Rights and Control
of TYSABRI® |
|
|
|
|
|
Potential Lilly Investment Would Further Expand
Indianapolis Insulin Manufacturing Operations |
|
|
|
|
|
|
